Targeting Epigenetics to Cure HIV-1: Lessons From (and for) Cancer Treatment

J. Peter Svensson *

Department of Biosciences and Nutrition, Karolinska Institutet (KI), Huddinge, Sweden

The Human Immunodeficiency Virus type 1 (HIV-1) integrates in the host genome as a provirus resulting in a long-lived reservoir of infected CD4 cells. As a provirus, HIV-1 has several aspects in common with an oncogene. Both the HIV-1 provirus and oncogenes only cause disease when expressed. A successful cure of both cancer and HIV-1 includes elimination of all cells with potential to regenerate the disease. For over two decades, epigenetic drugs developed against cancer have been used in the HIV-1 field to modulate the state of the proviral chromatin. Cells with an intact HIV-1 provirus exist in three states of infection: productive, inducible latent, and non-inducible latent. Here focus is on HIV-1, transcription control and chromatin structure; how the inducible proviruses are maintained in a chromatin structure that allows reactivation of transcription; and how transcription switches between different stages to allow for an abundance of different transcripts from a single promoter. Recently it was shown that a functional cure of HIV can be achieved by encapsulating all intact HIV-1 proviruses in heterochromatin, giving hope that epigenetic interventions may be used to end the HIV-1 epidemic.

Keywords: HIV cure, cancer, epigenetics, chromatin, transcription

INTRODUCTION

HIV-1 infection increases a person’s risk of acquiring certain types of cancer (Hernández-Ramírez et al., 2017). However, HIV-1 does not tend to cause cancer directly, unlike Human Papilloma Virus (HPV) causing cervical cancer, Hepatitis B or C virus triggering liver cancer, or Human T-lymphotropic virus type-1 (HTLV-1) leading to adult T cell leukemia/lymphoma. Even though HIV-1 is not an oncogenic virus, the HIV-1 integrates in the host genome as a provirus in the reservoir of infected cells and as a provirus HIV-1 shares many features of an oncogene. Both the HIV-1 provirus and oncogenes are harmless in a repressed, latent form and cause disease only when expressed. Successful anticancer therapy necessitates the elimination of all cells with tumor-regenerating potential. Paralleling cancer therapy, to hinder propagation of HIV-1, all the infected cells that can regenerate new infectious HIV-1 particles have to be removed. However, cells with proviruses having incapacitating mutations or those that are permanently silenced may be left untouched (Jiang et al., 2020; Sarabia et al., 2021). Erasing the pathological phenotype can in both cases occur through cell death, or by rendering the cell incapable of producing disease-generating transcripts or proteins. For a functional cure, the therapeutic targets are only the cells able to transcribe intact proviruses or oncogenes.
SPECIFIC CELLS TO BE ELIMINATED

Considering the therapeutic target the total reservoir of HIV-infected cells would require a 10,000-fold reduction to achieve a cure according to modelling (Hill et al., 2014). Despite promising in vitro results, therapeutic interventions in several clinical trials show no effect to reduce the reservoir or HIV-1 DNA levels (Elliott et al., 2014; Rasmussen et al., 2014; Vibholm et al., 2019). These results cast doubts on the possibility of a complete depletion of the HIV-1 infected cells. The first problem towards an HIV-1 cure is to identify the reservoir of infected cells. On the surface of cells with productive HIV-1 infection, high levels of PD-1, LAG-3, and TIGIT are found (Chomont et al., 2009; Chew et al., 2016; Fromentin et al., 2016; Fromentin et al., 2019). These three surface markers are immune checkpoint molecules, that downregulate the immune response to maintain self-tolerance and prevent hyper-immune activation (Leach et al., 1996; Greenwald et al., 2005). Cancer cells express these surface markers to evade immune response, and immune checkpoint inhibitors (ICIs) are used as anti-cancer immunotherapy (Topalian et al., 2012). The effect of ICIs on the HIV-1 reservoir is unknown but expected to only target the productively infected cells. CD32 is another surface molecule found enriched at productively HIV-infected cells but its function is unclear at this stage (Abdel-Mohsen et al., 2018).

The complexity of the HIV-1 reservoir hinders quantifications of cells with inducible provirus able to generate infectious viruses. The most commonly used PCR-derived methods generally overestimate the actual rebound reservoir. A detailed analysis of the reservoir reveals that most proviruses are defective (Ho et al., 2013; Imamichi et al., 2014; Imamichi et al., 2016; Bruner et al., 2016; Hiener et al., 2017; Pollack et al., 2017; Bruner et al., 2019). Even full length sequencing of intact proviruses overestimates the inducible reservoir as many of these proviruses are permanently silenced (de Verneuil et al., 2018; Jiang et al., 2020; Sarabia et al., 2021). The defective proviruses are unable to propagate HIV-1, even though they are able to produce truncated or chimeric proteins and trigger the immune response (Imamichi et al., 2016; Pollack et al., 2017). However, these cells are still clinically relevant as they exhaust the cytotoxic CD8 T cells. To improve therapy, we need to disentangle the reservoir of cells with defective and intact HIV-1 provirus. In this review, focus is on the reservoir of cells able to generate infectious HIV-1 particles, much like the “cancer stem cells” in a cancer setting.

THE PROMISE OF REPRESSIVE CHROMATIN

A small group of people living with HIV-1—“elite controllers” (ECs)—are able to spontaneously control the infection. The most common mechanism of spontaneous viral control is through specific protective HLA class 1 alleles (International HIV Controllers Study et al., 2010). The EC group also have individuals that control proviral expression (Jiang et al., 2020). This subgroup of ECs has the majority of intact proviruses encoded within heterochromatin regions. Heterochromatin is generally inert, and transitions between chromatin states predominantly occur during differentiation or development. Some ECs are able to long-term control the provirus in heterochromatin, either by targeting the integrants to repressed regions or, more likely, by eliminating the integrants in active regions and retaining the non-expressed proviruses (Jiang et al., 2020). This demonstrates that eliminating the provirus in non-heterochromatin may be a way towards a long-term ART-free remission. If we therapeutically can mimic these ECs by epigenetic silencing of the proviruses, we would achieve a functional HIV-1 cure, according to the “lock-and-block” strategy.

PROVIRAL INTEGRATION IS GUIDED BY HOST PROTEINS

Normally the provirus is not targeted to the silent chromatin regions. The integrations sites have been thoroughly mapped to open chromatin regions (Chen et al., 2017; Battivelli et al., 2018). The integration is guided by the affinity of the viral integrase to host proteins, notably LEDGF, HRP-2, and histones (Shun et al., 2007; Schrijvers et al., 2012; Benleulmi et al., 2017). These host proteins are present at sites of transcriptional activity. HIV-1 provirus integration also occurs in other open structures such as enhancers, possibly by DNA accessibility or other yet undefined factors (Vansant et al., 2020). Within the 3D structure of the nucleus, proviral integration occurs predominantly in the nuclear periphery, within the permissive chromatin regions in proximity to nuclear pores (Dieudonne et al., 2009; Lucic et al., 2019).

HIV-1 INTERACTS WITH DNA DAMAGE RESPONSE PATHWAYS

The HIV-1 capsids pass through the nuclear pores intact by interaction with CPSF6, before they are uncoated in the nucleus and integrated in the host genome (Lee et al., 2010; Bejarano et al., 2019; Zila et al., 2021). For the provirus to integrate, a double strand DNA break is required. HIV-1 integration is linked to RAD51 (Thierry et al., 2015), and through the viral Vpr protein, HIV-1 extensively engages several DNA damage response pathways (Li et al., 2020). Vpr plays a key role by inhibiting specific pathways of the DNA repair and also inducing cell cycle arrest and upregulating p21 (Vázquez et al., 2005). Expression of p21 has been found to prevent HIV-1 infection in ECs (Chen et al., 2011). Also by treating macrophages with topoisomerase inhibitors used against cancer, p21 is upregulated which in turn prevents HIV-1 integration (Mlcochova et al., 2018).

CONDITIONS THAT PREVENT PROVIRAL EXPRESSION

The integration site is a strong predictor of proviral expression, as chromatin modifications at the integration site spread over the proviral sequence (Jordan et al., 2001; Schröder et al., 2002;
Lewinski et al., 2005; Brady et al., 2009). Because the HIV-1 virus targets active cells and integration occurs in active chromatin regions, conditions are beneficial for immediate viral production. Analogously to oncogene expression, three conditions need to be met for viral production: metabolically active cells, availability of transcription factors and a permissive chromatin environment (Figure 1A). Lack of any of these three conditions will lead to proviral latency. As active cells return to quiescence, the metabolism shifts and transcription factors such as NFκB, with multiple binding sites in the HIV-1 promoter, are degraded (Chun et al., 1995; Shan et al., 2017). Even though the provirus is predominantly integrated in open regions, in time the provirus takes on a compact structure, and heterochromatin defining histone modifications appear on the proviral chromatin (Lindqvist et al., 2020). The lysines of histone H3 at position 9 and 27 (H3K9, H3K27) become methylated, representing distinctive heterochromatin structures. These epigenetic marks have been thoroughly described in the context of latent HIV-1 (du Chene et al., 2007; Marban et al., 2007; Pearson et al., 2008; Kauder et al., 2009; Tyagi et al., 2010; Friedman et al., 2011; Tripathy et al., 2015; Bouchat et al., 2016; Kessing et al., 2017; Nguyen et al., 2017; Taura et al., 2019).

**FIGURE 1 |** Controlling the proviral/oncogenic activity during T cell activation. (A) A heterogeneous population of cells can switch between different levels of activity resulting in changes of 1) the metabolic state of the cell, 2) the permissiveness of the chromatin of the provirus/oncogene that can adopt heterochromatin, euchromatin or poised chromatin structures, and 3) the availability of the transcriptional machinery, including transcription factors but also elongation, splicing and polyadenylation factors. (B) In the nucleus, the genetic locus of the provirus/oncogene in found in heterochromatin, poised chromatin (non-productive), or euchromatin (productive). Upon cell activation, the poised chromatin can allow productive transcription whereas the heterochromatin remains inactive. Transitioning between chromatin states (maroon arrows) is generally not associated with cell activation, instead it is caused by (de-) differentiation or chromatin resetting and can be induced by epigenetics drugs such as inhibitors of HDACs, BET domains, or DNMTs.

**PROVIRAL LATENCY IS INDUCED THROUGH INVADING CHROMATIN MARKS**

Methylated H3K9 serves as a binding platform for heterochromatin protein 1 (HP1), which has three isoforms, α, β and γ. HP1α/β are found at compact and inert heterochromatin, mainly in differentiated cells. The observed chromatin compaction in primary cells suggests that HP1α/β accumulate at the provirus (Lindqvist et al., 2020). The HP1γ isoform deviates from the other isoforms in that it is found at H3K9me3 chromatin in transcribed regions, often during development. Depleting HP1γ in cells from ART treated people living with HIV-1 leads to latency reversal (du Chene et al., 2007). This is one example where the provirus adopts features of undifferentiated cells to adopt a more plastic chromatin structure.

Heterochromatin marks spread across neighboring nucleosomes through e.g., the Human Silencing Hub (HUSH) complex. The HUSH complex is made up of the subunits MPP8 and TASOR. MPP8 recognizes H3K9me3 and TASOR binds to nascent RNA (Douse et al., 2020). In combination, this leads to HUSH being recruited to expressed H3K9me3-marked chromatin. MPP8 in turn recruits the methyltransferase SETDB1 to methylate H3K9 residues of adjacent nucleosomes. In this manner transcriptionally active genetic elements adjacent to heterochromatin are silenced (Tchasovnikarova et al., 2015). Alternatively, Polycomb repressive complex II (PRC2)-mediated H3K27me3 can silence the provirus (Friedman et al., 2011; Kumar et al., 2015; Tripathy et al., 2015; Nguyen et al., 2017). In contrast to constitutively silenced H3K9me3-chromatin, H3K27me3 is found at facultative heterochromatin. PRC2 is frequently mutated or overexpressed in various cancers, including lymphoma and prostate cancer. Small molecules targeting PRC2 are being developed as anticancer therapeutics (Martin et al., 2020). These molecules also have a potential in HIV-1 therapy by preventing heterochromatin from invading the provirus, and thus preventing re-activatable HIV-1 latency.

**PROVIRAL LATENCY IS INDUCED BY DE NOVO SILENCING**

Apart from extending chromatin domains, host mechanisms exist to directly silence foreign elements. Retroviruses, endogenous retroviruses (ERVs), or retrotransposons are targeted by KRAB-ZFP proteins. These small proteins consist of a Zinc finger protein (ZFP) that recognizes specific DNA sequences, and a Krüppel-associated box (KRAB), that recruits a cascade of proteins including SETDB1 to actively silence foreign DNA sequences (Wolf and Goff, 2009; Castro-Diaz et al., 2014; Jacobs et al., 2014; Wolf et al., 2015; Imbeault et al., 2017). A large proportion of the human genome consists of these KRAB-ZFP but no KRAB-ZFP is yet found to recognize HIV-1 sequences.

The role of DNA methylation in silencing HIV-1 is debated (LaMere et al., 2019). Members of the DNA methyltransferase (DNMT) family are often deregulated in cancer and upon HIV-1
infection (Fang et al., 2001; Zhang et al., 2015). The viral Tat protein is able to induce expression of DNMT3 and subsequent DNA hypermethylation (Luzzi et al., 2014). DNMT inhibitors are currently used in the treatment of myelodysplastic syndrome and acute myeloid leukemia. Other regulator of methylation, of both DNA and histones, are the IDH1/2 proteins (Xu et al., 2011). Mutations of these metabolic proteins are frequently found in many types of cancer, and targeted inhibitors of the mutation forms of IDH1/2 are in clinical trials (Raineri and Mellor, 2018). IDH1 has been implicated in HIV-1 infection (Chinn et al., 2010) but its role is yet to be determined. Recently a variant of IDH1/2 was found to engage at the long terminal repeat (LTR) of the HIV-1 provirus. In addition to recruiting chromatin modifiers, CAF-1 may contribute to HIV-1 latency by forming phase-separated nuclear bodies (Ma et al., 2021).

MAINTAINING LATENCY IN AN OPEN CHROMATIN STRUCTURE

Other possibilities for HIV provirus to remain non-productive is to block the transcription machinery. The HIV-1 promoter contains regions that have been proposed to form stable G-quadruplexes. These structures prevent transcription and thus regulate promoter activity (Perrone et al., 2013). Also, enhancers are open structures that are transcribed but do not produce mRNAs to be translated. HIV-1 can make use of this strategy to maintain a poised latency (Lindqvist et al., 2020). By being encapsulated in enhancer chromatin (Chen et al., 2017; Battivelli et al., 2018), the HIV-1 provirus maintains a permissive chromatin structure without producing any viral proteins to activate an immune response. Short unspliced enhancer-like transcripts are being produced in latently infected resting CD4 cells (Yukl et al., 2018). The HIV-1 provirus has a splice donor just downstream of the transcription start site, as mammalian genes (Andersson et al., 2014). By ignoring this splice site, the nascent transcripts acquire enhancer transcript features. These persistent transcripts mark the cells responsible for viral rebound as these transcripts predict time to HIV-1 rebound (Moron-Lopez et al., 2019; Pasternak et al., 2020).

RESERVOIR PROLIFERATION AND EVOLUTION

Maintenance of the reservoir in people living with HIV-1 under ART is driven by cellular proliferation (Kearney et al., 2016; De Scheerder et al., 2019). This proliferation, controlled by host mechanisms, is both homeostatic and antigen-driven (Simonetti et al., 2020). Antigen-driven proliferation can be from HIV-1 antigens, but also from other unrelated antigens. Here the provirus act as a passenger of T cell proliferation. With time under ART, the reservoir evolves and intact proviruses as well as proviruses with an intact 5' region are lost (Bruner et al., 2019; Pinzone et al., 2019). Possibly these cells express viral proteins toxic to the cell, or they are recognized by CD8 cells. Reservoir cells with a mutated HIV-1 5' region are more resilient. Through the intact LTR promoter, these cells may express viral proteins encoded in the 3' provirus, notably Nef, an accessory protein. Nef is able to force internalization of HLA molecules, rendering cells invisible to the immune system. Nef-expressing cells do not decay in time, whereas cells expressing Gag, Pol, Env are eliminated (Thomas et al., 2017; Stevenson et al., 2021). Like in cancer, the HIV-1 reservoir is under evolutionary pressure to evade recognition (Mylvaganam et al., 2019). T cell responses shape the long-term HIV-1 cell population (Akahoshi et al., 2020).

POISED CHROMATIN STRUCTURES ARE SUSCEPTIBLE TO HIV-1 PROVIRUS ACTIVATION

T cell activation results in increased metabolic activity and activation of a diverse set of transcription factors, including NFκB. Activation of the HIV-1 infected cells correlates with proviral activation. Metabolic activity such as mTOR signaling is required for latency reversal (Besnard et al., 2016). Latency reversal recapitulates the metabolic dysregulation induced during productive infection (Shytaj et al., 2020). Activation of T cells cause changes among the activating chromatin marks such as H3K27ac on the HIV-1 provirus (Lindqvist et al., 2020). However, cellular activation does not generally lead to transition between proviral chromatin states. In contrast to wide-spread chromatin state transition during T cell differentiation where cells shift from naïve to memory T cells, short-term T cell activation does not correlate with global changes in chromatin states (Barski et al., 2009; Cuddapah et al., 2010). Genes inducible by T cell activation are instead associated with poised promoters in resting T cells.

Poised chromatin is defined by the simultaneous presence of active and repressive epigenetic marks, such as post-translational modifications of histones or histone variants. The histone variant H2A.Z is primarily found at promoters but also in coding regions of inducible genes (Sadeghi et al., 2011). H2A.Z is less stable than the canonical H2A and histone turnover will locally allow processive transcription (Svensson et al., 2015). Transcription through chromatin can affect histone turnover depending on the protein complexes associated with RNAPII (Sadeghi et al., 2015). The PAF1 complex has been suggested to evict old histones and thereby make chromatin more accessible to permit transcription of previously non-permissive but poised chromatin. This mechanism could explain the requirement of PAF1 for Tat-mediated HIV transcription (Sobhian et al., 2010).

TRANSCRIPTION PHASES IN HIV-1 PROVIRAL ACTIVATION

Although accessible proviral chromatin is necessary for engagement of the transcription machinery, it is not sufficient for proviral latency reversal (Battivelli et al., 2018; Sarabia et al., 2021).
Upon cellular activation, proviral transcription continue to depend on host mechanisms, through initiation, elongation, splicing and poly-adenylation (Yukl et al., 2018). The transcription cycle of the HIV provirus has several phases. Early in the proviral activation, the nascent HIV-1 transcripts are transcribed at multiple positions (Moron-Lopez et al., 2020). These transcripts translate into early viral proteins needed to suppress immune response and upregulate HIV-1 transcription. In later stages of proviral transcription, the splicing machinery is inactivated to produce transcripts encoding late proteins, as well as the full-length HIV-1 genome. The factors inactivating the spliceosome are currently unknown. Whereas spliced transcripts can pose as host mRNA, the full HIV genome and intron-retaining transcripts would be recognized in the cell as foreign or malign. Differential intron retention is detected in almost all cancers (Dvinge and Bradley, 2015), but it is also active in differentiation (Yap et al., 2012; Wong et al., 2013). In CD4 T cells, intron retention is accepted in resting cells, but reduced as the cells activate (Ni et al., 2016). Nuclear export of unspliced HIV-1 transcripts is facilitated by the viral Rev protein, and proximity to the nuclear pore additionally assists in rapid export from the nucleus (Lucic et al., 2019). The oncogene MYC uses a similar mechanism to export intron-containing transcripts from nucleus (Scholz et al., 2019).

THERAPEUTIC TARGETS FOR CHROMATIN STATE REVERSAL

A strategy to cure HIV-1 is the “shock and kill” approach, where cells are treated with a latency reversal agent (LRA) to shock the provirus into expression, followed by killing of the cell by either the immune system or a second therapeutic such as broadly neutralizing antibodies (Sok et al., 2016). To stimulate proviral expression in latently infected cells, several drugs developed against cancer have been used as LRAs. Exposing latently HIV-1 infected cells to epigenetic anti-cancer drugs such as inhibitors of HDACs, DNMTs, and combinations thereof stimulates proviral expression (Jiang et al., 2015; Bouchat et al., 2016; Moron-Lopez et al., 2019). These drugs lead to a more open chromatin structure, suggesting a closed chromatin configuration prevents transcription in at least a subset of reservoir cells. Still, however, only a minority of infected cells also reactivate the provirus (Battivelli et al., 2018; Sarabia et al., 2021). An alternative strategy to achieve a functional cure is termed “lock-and-block”. Here the goal is to permanently silence the provirus so to block viral reactivation and prevent HIV-1 transmission in the absence of ART. This strategy has been attempted by e.g. inhibitors of BET or mTOR (Besnard et al., 2016; Niu et al., 2019), or inhibitors of Tat (Kessing et al., 2017).

DISCUSSION

After long-term ART, intact proviruses endure in infected cells in people living with HIV-1, reminiscent of an oncogene. Even after strong activating signals, proviruses maintain latency. This inertia remains despite nutrients and transcription factors, and predominant integration into open chromatin regions. During initial integration and over time, proviral chromatin adopts different chromatin configurations. As CD4 T cells go from resting to activated, proviruses act according to chromatin state (Figure 1B). Proviruses in heterochromatin likely remain in a latent state without producing rebound viruses. Any processive proviral transcription from resting cells is likely to continue during cell activation. Although rare, spliced polyadenylated HIV-1 transcripts have been observed in resting CD4 T cells (Yukl et al., 2018). To remain in long-term circulation, these cells need to deploy mechanisms to actively evade the immune response. For HIV-1 cure purposes, the most interesting reservoir fraction come from cells with the proviruses contained in poised chromatin. Poised chromatin may be associated with unstable promoter histones or being encapsulated in an enhancer-like structure that maintain open accessible chromatin while still avoiding mRNA expression. This fraction of poised proviruses is able to escape immune detection in the resting cell as no viral proteins are expressed, and upon activation produce rebound HIV-1 viruses.

The goal in both cancer therapy and HIV-1 cure is to contain and destroy cells with potential to spread the disease, in a heterogeneous cell population. Both cancer and HIV-1 are evading the immune response. The provirus is using stem cell-like properties and the same pathways as cancer to maintain an open chromatin structure at the provirus. The HIV cure field explores ways in which aberrant transcription occur via host mechanisms. Historically HIV-1 has for example been used to decipher the transcription elongation (Kao et al., 1987; Kamine et al., 1996; Mancebo et al., 1997), the role of acetylation (Yamamoto and Horikoshi, 1997; Kiernan et al., 1999; Ott et al., 1999), and promoter remodeling (Verdin et al., 1993; Conrad et al., 2017). The HIV-1 provirus locus continues to be widely used as an appreciated model to understand the host chromatin and transcription machinery of mammalian cells.

AUTHOR CONTRIBUTIONS

The author confirms being the sole contributor of this work and has approved it for publication.

FUNDING

This work was supported by Vetenskapsrådet (2019-00991), Cancerfonden (19 0412 P), Center for Innovative Medicine (FoUI-954473), and Stiftelsen Läkare mot AIDS Forskningsfond (FOb2020-0004).

ACKNOWLEDGMENTS

Apart from the funders, I would like to thank Luca Love and Bianca Jütte for critical reading of the manuscript.
REFERENCES

Abdel-Mohsen, M., Kurt-Cervantes, L., Grau-Exposito, J., Spivak, A. M., Nell, R. A., Tomasencu, C., et al. (2018). CD32 is Expressed on Cells With Transcriptionally Active HIV But Does Not Enrich for HIV DNA in Resting T Cells. Sci. Transl. Med. 10, eaar46799. doi: 10.1126/scitransmed.aar46799

Akalhoshi, T., Gatanaga, H., Kuse, N., Chikata, T., Koyanagi, M., Ishizuka, N., et al. (2020). T-Cell Responses to Sequentially Emerging Viral Escape Mutants Shape Long-Term HIV-1 Population Dynamics. PLoS Pathog. 16, e1009177. doi: 10.1371/journal.ppat.1009177

Andersson, R., Gebhard, C., Miguel-Escalada, I., Hoef, I., Bornholdt, J., Boyd, M., et al. (2014). An Atlas of Active Enhancers Across Human Cell Types and Tissues. Nature 507, 455–461. doi: 10.1038/nature12787

Barski, A., Jothi, R., Cuddapah, S., Cui, K., Roh, T.-Y., Schones, D. E., et al. (2009). Chromatin Poises mRNA- and Protein-Encoding Genes for Expression. Genome Res. 19, 1742–1751. doi: 10.1101/gr.090951.109

Batelli, E., Dahabieh, M. S., Abdel-Mohsen, M., Svensson, J. P., Da Silva, I. T., Cohn, L. B., et al. (2018). Distinct Chromatin Functional States Correlate With HIV latency Reactivation in Infected Primary CD4(+) T Cells. Elife 7, e34655. doi: 10.7554/eLife.34655

Bejarano, D. A., Peng, K., Laketa, V., Börner, K., Jost, K. L., Lucic, B., et al. (2019). HIV-1 Nuclear Import in Macrophages is Regulated by CPSF6–capsid Interactions At the Nuclear Pore Complex. Elife 8, e18000. doi: 10.7554/eLife.43754

Benedulmi, M. S., Matsyiak, J., Robert, X., Miskey, C., Mauro, E., Lapuлерe, D., et al. (2017). Modulation of the Functional Association Between the HIV-1 Intasome and the Nucleosome by Histone Amino-Terminal Tails. Retrovirology 14, 54. doi: 10.1186/s12977-017-0378-x

Besnard, E., Hakre, S., Kampmann, M., Lim, H. W., Hosmane, N. N., Martin, A., et al. (2016). The Mtor Complex Controls HIV latency. Cell Host Microbe 20, 785–797. doi: 10.1016/j.chom.2016.11.001

Bouchat, S., Delacourt, N., Kula, A., Darcis, G., Van Driessche, B., Corazza, F., et al. (2016). Sequential Treatment With 5-aza-2-deoxycytidine and Decetylase Inhibitors Reactivates HIV-1. EMBO Mol. Med. 8, 117–138. doi: 10.15252/emmm.201505557

Brady, T., Agosto, L. M., Malani, N., Berry, C. C., O’Doherty, U., and Bushman, F. (2009). HIV Integration Site Distributions in Resting and Activated CD4+ T Cells Infected in Culture. AIDS Lond. Engl. 23, 1461–1467. doi: 10.1097/01.aids.00003383283ca8f2

Bruner, K. M., Murray, A. J., Pollack, R. A., Soliman, M. G., Brady, T., Agosto, L. M., Malani, N., et al. (2011). Gene expression differences between CD4(+) T cells in elite controllers and non-controllers. Clin. Immunol. 138, 231–240. doi: 10.1016/j.clim.2010.11.005

Chen, H., Li, C., Huang, J., Cung, T., Seiss, K., Beamon, J., et al. (1995). In Vivo Fate of HIV-1-Infected T Cells: Quantitative Analysis of the Transition to Stable Latency. Nat. Med. 1, 1284–1290. doi: 10.1038/nm1295-2824

Connolly, R. J., Fozouzi, P., Thomas, S., Sy, H., Zhang, Q., Zhou, M. M., et al. (2017). The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin-Remodeling Complexes. Mol. Cell 67, 1001–1012.e6. doi: 10.1016/j.molcel.2017.07.025

Cuddapah, S., Barski, A., and Zhao, K. (2010). Epigenomics of T Cell Activation, Differentiation, and Memory. Curr. Opin. Immunol. 22, 341–347. doi: 10.1016/j.coi.2010.02.007

De Scheeder, M. A., Vranckx, B., Dellicour, S., Schuhl, T., Lee, E., Shao, W., et al. (2019). A single-exposure HIV rebound is predominantly fueled by genetically identical viral sequences. Cell Host Microbe 26, 347–358.e7. doi: 10.1016/j.chom.2019.08.003

de Verneuil, A., Migraine, J., Mammano, F., Molina, J. M., Gallien, S., Mouquet, H., et al. (2018). Genetically Intact But Functionally Impaired HIV-1 Env Glycoproteins in the T-Cell Reservoir. J. Virol. 92, e01684–17. doi: 10.1128/JVI.01684-17

Diedonne, M., Mairui, P., Biancotto, C., Knezevich, A., Kula, A., Lusci, M., et al. (2013). Transcriptional Competence of the Integrated HIV-1 Provirus At The Nuclear Periphery. EMBO J. 28, 2231–2243. doi: 10.1038/embj.2009.141

Douse, C. H., Tchachovnikarova, I. A., Timms, R. T., Protasio, A. V., Szczynska, M., Prigozhin, D. M., et al. (2020). TASOR is a pseudo-PARP That Directs HUSH Complex Assembly and Epigenetic Transposition Control. Nat. Commun. 11, 4940. doi: 10.1038/s41467-020-18761-6

Durante, S., Bouchat, S., Delacourt, N., Kula, A., Darcis, G., Van Driessche, B., Corazza, F., et al. (2016). Sequential Treatment With 5-aza-2-deoxycytidine and Decetylase Inhibitors Reactivates HIV-1. EMBO Mol. Med. 8, 117–138. doi: 10.15252/emmm.201505557

Friedman, J., Cho, W. K., Chu, C. K., Keedy, K. S., Archin, N. M., Margolis, D. M., et al. (2011). Epigenetic Silencing of HIV-1 by the Histone H3 Lysine 27 Deacetylase Inhibitors Reactivates HIV-1. EMBO Rep. 12, e41800. doi: 10.7554/electrons.2019.08.003

Greenwald, R. J., Freeman, G. J., and Sharpe, A. H. (2005). The B7 Family Revisited. Annu. Rev. Immunol. 23, 515–548. doi: 10.1146/annurev.immunol.23.021704.115611

Hernández-Ramírez, R. U., Shiel’s, M. S., Dubrow, R., and Engels, E. A. (2017). Cancer Risk in HIV-infected People in the USA From 1996 to 2012: A Population-Based, Registry-Linkage Study. Lancet HIV 4, e495–e504. doi: 10.1016/S2352-3018(17)30125-X

Hiener, B., Horsburgh, B. A., Eden, J. S., Barton, K., Schlub, T. E., Lee, E., et al. (2017). Identification of Genetically Intact HIV-1 Proviruses in Specific CD4(+) T Cells From Effectively Treated Participants. Front. Immunol. 8, 347. doi: 10.3389/fimmu.2017.00347

Hill, A. L., Rosenblom, D. J. S., Fu, F., Nowak, M. A., and Siliciano, R. F. (2014). Predicting the Outcomes of Treatment to Eradicate the Latent Reservoir for HIV-1. Proc. Natl. Acad. Sci. U. S. A. 111, 13475–13480. doi: 10.1073/pnas.1406663111

Ho, Y. C., Shan, L., Hosmane, N. N., Wang, J., Laskey, S. B., Rosenblom, D. J. S., et al. (2013). Replication-Competent Noninduced Proviruses in the Latent
Reservoir Increase Barrier to HIV-1 Cure. Cell 155, 540–551. doi: 10.1016/j.cell.2013.09.020

Imamichi, H., Desvar, R. L., Ader博士, J. W., Rehm, C. A., O’Doherty, U., Puxinos, E. E., et al. (2016). Defective HIV-1 Proviruses Produce Novel Protein-Coding RNA Species in HIV-infected Patients on Combination Antiretroviral Therapy. Proc. Natl. Acad. Sci. U. S. A. 113, 8783–8788. doi: 10.1073/pnas.160957113

Imamichi, H., Natarajan, V., Ader博士, J. W., Rehm, C. A., Lempicki, R. A., Das, B., et al. (2014). Lifespan of Effector Memory CD4+ T Cells Determined by Replication-Independent Integrated HIV-1 Provirus. Aids 28, 1091–1099. doi: 10.1097/QAD.0000000000000223

Imbeault, M., Helleboid, P. Y., and Trono, D. (2017). KRAB Zinc-Finger Proteins Contribute to the Evolution of Gene Regulatory Networks. Nature 543, 550–556. doi: 10.1038/nature21683

International HIV Controllers Study, Pereyra, F., Jia, X., McLaren, P. J., Telenti, A., de Bakker, P. I. W., et al. (2016). The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science 350, 1551–1557. doi: 10.1126/science.a1952711

Jacobs, F. M., Greenberg, D., Nguyen, N., Hauessler, M., Ewing, A. D., Katzman, S., et al. (2014). An Evolutionary Arms Race Between KRAB Zinc-Finger Genes ZNF91/93 and SVA/L1 Retrotransposons. Nature 516, 242–245. doi: 10.1038/nature13760

Jiang, C., Lian, X., Gao, C., Sun, X., Einkauf, K. B., Chevalier, J. M., et al. (2020). Distinct Viral Reversions in Individuals With Spontaneous Control of HIV-1 Nature 585, 261–267. doi: 10.1038/s41586-020-2651-8

Jiang, G. C., Menes, E. A., Kaiser, P., Wong, D. P., Tang, Y. Y., Cai, L., et al. (2015). Synergistic Reactivation of Latent HIV Expression by Ingol-I-3-Angetale, Pep005, Targeted NF-Kb Signaling in Combination With JQI Induced p-TEFb Activation. PloS Pathog. 11, e1005066. doi: 10.1371/journal.ppat.1005066

Jordan, A., Defechereux, P., and Verdin, E. (2001). The Site of HIV-1 Integration in the Human Genome Determines Basal Transcriptional Activity and Response to Tat Transactivation. EMBO J. 20, 1726–1738. doi: 10.1093/emboj/20.7.1726

Kamine, J., Elangovan, B., Subramanian, T., Coleman, D., and Chinnadurai, G. (1996). Identification of a Cellular Protein That Specifically Interacts With the Essential Cysteine Region of the HIV-1 Tat Transactivator. Virology 216, 357–366. doi: 10.1006/viro.1996.0071

Kao, S. Y., Calman, A. F., Luciw, P. A., and Peterlin, B. M. (1987). Antitermination of Transcription Within the Long Terminal Repeat of HIV-1 by Tat Gene Product. Nature 330, 489–493. doi: 10.1038/330489a0

Kauder, S. E., Ader博士, A., Lempicki, R. A., Maunder, L., et al. (2019). Recruitment of Chromatin-Modifying Enzymes by CTIP2 Promotes Phase-Separated Suppressive Nuclear Bodies. EMBO J. e100632. doi: 10.15252/embj.201910632

Kadner, S. E., Bosque, A., Lindqvist, A., Planelles, V., and Verdin, E. (2009). The Site of HIV-1 Integration Barrier to HIV-1 Cure. Nat. Immunol. 10, 4059. doi: 10.1038/ni.1967-019-12046-3

Luzzi, A., Morettini, F., Gazaneo, S., Mundo, L., Onnis, A., Mannucci, S., et al. (2014). HIV-1 Tat Induces DNMT Over-Expression Through microRNA Dysregulation in HIV-related non Hodgkin Lymphomas. Infect. Agent. Cancer 9, 41. doi: 10.1186/1750-9378-9-41

Ma, X., Chen, T., Peng, Z., Wang, Z., Liu, J., Yang, T., et al. (2021). Histone Chaperone CAP1-F1 Promotes HIV-1 Latency by Leading the Formation of Phase-Separated Suppressive Nuclear Bodies. EMBO J. e100632. doi: 10.15252/embj.201910632

Mancebo, H. S., Lee, G., Flygare, J., Tomassini, J., Lui, P., Zhu, Y., et al. (1997). P-TEFb Kinase is Required for HIV Tat Transcriptional Activation In Vivo and In Vitro. Genes Dev. 11, 2633–2644. doi: 10.1101/gad.11.20.2633

Marban, C., Suzanne, S., Defueild, F., de Walque, S., Redel, L., VanLint, C., et al. (2007). Recruitment of Chromatin-Modifying Enzymes by CTIP2 Promotes HIV-1 Transcriptional Silencing. EMBO J. 26, 412–423. doi: 10.1038/sj.emboj.7601516

Martin, M. C., Zeng, G., Yu, J., and Schiltz, G. E. (2020). Small Molecule Approaches for Targeting the Polyclom Repressive Complex 2 (PRC2) in Cancer. J. Med. Chem. 63, 15344–15370. doi: 10.1021/acs.jmedchem.0c01344

Mochocova, P., Caswell, S. J., Taylor, I. A., Towers, G. J., and Gupta, R. K. (2018). DNA Damage Induced by Topoisomerase Inhibitors Activates SAMHD1 and Blocks HIV-1 Infection of Macrophages. EMBO J. 37, 50–62. doi: 10.15252/embj.201796880

Moron-Lopez, S., Kim, P., Sogaard, O. S., Tolstrup, M., Wong, J. K., and Yuki, S. A. (2019). Characterization of the HIV-1 Transcription Profile After Rimdopimid Administration in ART-suppressed Individuals. AIDS 33, 425–431. doi: 10.1097/QAD.0000000000002083

Moron-Lopez, S., Telwatte, S., Sarabia, I., Battivelli, E., Montano, M., Macedo, A. B., et al. (2020). Human Splice Factors Contribute to Latent HIV Infection in Primary Cell Models and Blood CD4+ T Cells From ART-treated Individuals. PloS Pathog. 16, e1009060. doi: 10.1371/journal.ppat.1009060

Mylaganam, G., Yanez, A. G., Maus, M., and Walker, B. D. (2019). Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. Front. Immunol. 10, 2109. doi: 10.3389/fimmu.2019.02109

Nguyen, K., Das, B., Dobrowolski, C., and Karn, J. (2017). Multiple Histone Lysozo Methyltransferases are Required for the Establishment and Maintenance of HIV-1 Latency. Microbiol. 8, e00133-17. doi: 10.1128/microbiolsf.00133-17

Niu, Q., Liu, Z., Alam, E., Fan, X., Chen, H., Endlsey, J., et al. (2019). Structure-Guided Drug Design Identifies a BBD4-selective Small Molecule That Suppresses HIV. J. Clin. Invest. 129, 3361–3373. doi: 10.1172/JCI120633

Ni, T., Yang, W., Han, M., Zhang, Y., Shen, T., Nie, H., et al. (2016). Global Intron Retention Mediated Gene Regulation During CD4+ T Cell Activation. Nucleic Acids Res. 44, 6817–6829. doi: 10.1093/nar/gkw591

Ott, M., Schönlzer, M., Garnica, J., Fischle, W., Emilians, S., Rackwitz, H. R., et al. (1999). Acetylation of the HIV-1 Tat Protein by p300 is Important for its Antitumor Immunity by CTLA-4 Blockade. J. Virol. 73, 6610–6619. doi: 10.1128/JVI.73.11.6610–6619.2005

Li, D., Lopez, A., Sandoval, C., Nichols Doyle, R., and Fregoso, O. J. (2020). HIV Vpr Modulates the Host DNA Damage Response At Two Independent Steps to Damage DNA and Repress Double-Strand DNA Break Repair. mBio 11, e00940–20. doi: 10.1128/mbio.00940-20

Lindqvist, B., Svensson Akusjarvi, S., Sonnerborg, A., Dimitriou, M., and Svensson, J. P. (2020). Chromatin Maturation of the HIV-1 Provirus in Primary Resting CD4+ T Cells. PLoS Pathog. 16, e1008264. doi: 10.1371/journal.ppat.1008264
Incorporates a Motif Associated With CCR5 Binding and Its Camouflaging Glycans. Immunity 45, 31–45. doi: 10.1016/j.immuni.2021.06.026

Svensson, E. M., Ward, A. R., Truong, R., Thomas, A. S., Huang, S.-H., Dilling, T. R., et al. (2021). HEV-Specific T-cell Responses Reflect Substantive In Vivo Interactions With Antigen Despite Long-Term Therapy. JCI Insight. 6, e142640. doi: 10.1172/jci.insight.142640

Svensson, J. P., Shukla, M., Menendez-Benito, V., Norman-Axelsson, U., Audergon, P., Sinha, I. et al. (2015). A Nucleosome Turnover Map Reveals That the Stability of Histone H4 Lys20 Methylation Depends on Histone Recycling in Transcribed Chromatin. Genome Res. 25, 872–883. doi: 10.1101/ gr.188707.114

Taura, M., Song, E., Ho, Y. C., and Iwasaki, A. (2019). ApoBec3A Maintains HIV-1 Latency Through Recruitment of Epigenetic Silencing Machinery to the Long Terminal Repeat. Proc. Natl. Acad. Sci. U. S. A. 116, 2282–2289. doi: 10.1073/ pnas.1819386116

Tchasovnikarova, I. A., Timms, R. T., Mathews, N. J., Wals, K., Antrobus, R., Götgens, B., et al. (2015). Epigenetic Silencing by the HUSH Complex Mediates Position-Effect Variegation in Human Cells. Science 348, 1481. doi: 10.1126/science.aaa7227

Thierry, S., Benleulmi, M. S., Sinzelle, L., Thierry, E., Camales, C., Chaignepain, S., et al. (2015). Dual and Opposite Effects of Hrad51 Chemical Modulation on HIV-1 Integration. Chem. Biol. 22, 712–723. doi: 10.1016/ j.chembiol.2015.04.020

Thorisson, A. S., Jones, K. L., Gandhi, R. T., McMahon, D. K., Cyktor, J. C., Chan, D., et al. (2017). T-Cell Responses Targeting HIV Neurally Correlated With Infected Cell Frequencies After Long-Term Antiretroviral Therapy. PloS Pathog. 13, e1006629. doi: 10.1371/journal.ppat.1006629

Topalainen, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., et al. (2012). Safety, Activity, and Immune Correlates of anti-PD-1 Antibody in Cancer. N. Engl. J. Med. 366, 2443–2454. doi: 10.1056/nejmoa1200690

Tripathy, M. K., McManamy, M. E. M., Burch, B. D., Archim, N. M., and Margolis, D. M. (2015). H3K27 Demethylation At the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4(+) T Cells. J. Virol. 89, 8392–8405. doi: 10.1128/JVi.00572-15

Tyagi, M., Pearson, R. J., and Karn, J. (2010). Establishment of HIV Latency in Primary CD4(+) Cells is Due to Epigenetic Transcriptional Silencing and P-TEFb Restriction. J. Virol. 84, 6425–6437. doi: 10.1128/JVi.01519-09

Vansant, G., Chen, H. C., Zorita, E., Trejbalová, K., Miklík, D., Filion, G. et al. (2020). The Chromatin Landscape At the HIV-1 Provirus Integration Site Determines Viral Expression. Nuclear Acids Res. 48, 7801–7817. doi: 10.1093/ nar/gkaa536

Vázquez, N., Greenwell-Wild, T., Marinos, N. J., Swain, W. D., Naes, S., Ott, D. E., et al. (2005). Human Immunodeficiency Virus Type 1-Induced Macrophage Gene Expression Includes the p21 Gene, a Target for Viral Regulation. J. Virol. 79, 4479–4491. doi: 10.1128/JVI.79.12.4479–4491.2005

Verdin, E., Paras, P., and Vanlint, C. (1993). Chromatin Disruption in the Promoter of Human-Immunodeficiency-Virus Type 1 During Transcriptional Activation (Vol 12, Pg 3249). EMBO J, 12, 4900–4900. doi: 10.1002/1607-1993.1993.tb05994.x

Vibhorum, L. K., Konrad, C. V., Schleimann, M. H., Frattari, G., Windelmans, A., Klastrous, V., et al. (2019). Effects of 24-Wk Toll-like Receptor 9 Agonist Treatment in HIV Type 1+ Individuals. AIDS Lond. Engl. 33, 1315–1325. doi: 10.1097/QAD.00000000000002213

Wolf, D., and Goff, S. P. (2009). Embryonic Stem Cells Use ZFP809 to Silence Genes Dev. 24, 451. doi: 10.1101/gad.156510.7

Wong, J. J.-L., Ritchie, W., Ebner, O. A., Selbach, M., Wong, J. W. H., Huang, Y., et al. (2013). Orchestrated Intron Retention Regulates Normal Granulocyte Gene Expression Including the p21 Gene, a Target for Viral Regulation. J. Virol. 87, 154–168. doi: 10.1101/jci145254
Yamamoto, T., and Horikoshi, M. (1997). Novel Substrate Specificity of the Histone Acetyltransferase Activity of HIV-1-Tat Interactive Protein Tip60. *J. Biol. Chem.* 272, 30595–30598. doi: 10.1074/jbc.272.49.30595

Yap, K., Lim, Z. Q., Khandelia, P., Friedman, B., and Makeyev, E. V. (2012). Coordinated Regulation of Neuronal mRNA Steady-State Levels Through Developmentally Controlled Intron Retention. *Genes Dev.* 26, 1209–1223. doi: 10.1101/gad.188037.112

Yukl, S. A., Kaiser, P., Kim, P., Telwatte, S., Joshi, S. K., Vu, M., et al. (2018). HIV Latency in Isolated Patient CD4(+) T Cells may be Due to Blocks in HIV Transcriptional Elongation, Completion, and Splicing. *Sci. Transl. Med.* 10, eaap9927. doi: 10.1126/scitranslmed.aap9927

Zhang, Y., Li, S.-K., Yi Yang, K., Liu, M., Lee, N., Tang, X., et al. (2015). Whole Genome Methylation Array Reveals the Down-Regulation of IGFBP6 and SATB2 by HIV-1. *Sci. Rep.* 5, 10806. doi: 10.1038/srep10806

Zila, V., Margiotta, E., Turoňová, B., Müller, T. G., Zimmerli, C. E., Mattei, S., et al. (2021). Cone-Shaped HIV-1 Capsids are Transported Through Intact Nuclear Pores. *Cell* 184, 1032–1046.e18. doi: 10.1016/j.cell.2021.01.025

**Conflict of Interest:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Svensson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.